Dr. Murray Urowitz, of the University of Toronto University Health Network, Provides Overview of an Analysis of Data from a P...

RAANANA, Israel, October 28, 2015 /PRNewswire/ --

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, with a focus on treatments for autoimmune diseases, today announced that Dr. Murray Urowitz, of the University of Toronto University Health Network, provided the Lupus Foundation of America with a podcast overview of an analysis of data of a Phase II clinical study of XTL's clinical asset, hCDR1 (Edratide), for the treatment of lupus (SLE).

A copy of the podcast is available for listening at the following link:

http://www.lupus.org/podcasts/entry/safety-and-efficacy-of-hcdr1-edratide-in-patients-with-active-lupus

About XTL Biopharmaceuticals Ltd. ("XTL") 

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, with a focus on treatments for autoimmune diseases.

XTL is a public company, traded on the Nasdaq Capital Market (NASDAQ: XTLB) and the Tel Aviv Stock Exchange (TASE: XTL). XTL shares are included in the following indices: Tel-Aviv Biomed, Tel-Aviv MidCap, and Tel-Aviv Tech Index.

Cautionary Statement 

This press release may contain forward-looking statements, about XTL's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, XTL or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by XTL with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of XTL's authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause XTL's actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause XTL's actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements, including, but not limited to, the factors summarized in XTL's filings with the SEC and in its periodic filings with the TASE.  In addition, XTL operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control.  XTL does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise. Please see the risk factors associated with an investment in our ADSs or ordinary shares which are included in our Annual Report on Form 20-F as filed with the U.S. Securities and Exchange Commission on April 28 2015.

For further information, please contact:

Investor Relations, XTL Biopharmaceuticals Ltd.

Tel: [phone]
Email: [e-mail]
http://www.xtlbio.com

Arrowhead Business and Investment Decisions, LLC

140 Broadway, 46th Floor, New York, NY 10005

Daniel Renaud or Thomas Renaud
[phone]
[e-mail]
http://www.abid.co/NASDAQ.XTLB

SOURCE XTL Biopharmaceuticals Ltd

Copyright 2015 PR Newswire